Table of Contents
Kneeland Youngblood spent his early career in the emergency room. He graduated from Princeton University in 1978 with a degree in politics and science, then earned his medical degree from the University of Texas Southwestern Medical School in 1982. He practiced emergency medicine in Texas before deciding, in the mid-1990s, that the most consequential work he could do in healthcare would happen at the level of capital, not the clinic.
That pivot produced a business life most physicians never imagine. He co-founded Pharos Capital Group in 1997 with a clear thesis: back mid-market healthcare companies built to change how care was delivered and priced in underserved American communities. Nearly three decades later, Pharos manages over $1 billion in assets and has backed 58 companies. Along the way, Youngblood has collected board seats at some of the most prominent names in American business, received presidential appointments and built a personal portfolio that stretches from blockchain infrastructure to specialty pharmaceuticals.
These are the seven companies Kneeland Youngblood owns and controls.
1. Pharos Capital Group
At the center of Youngblood's financial life is Pharos Capital Group, the Dallas and Nashville-based private equity firm he co-founded in 1997. He serves as founding partner, chairman and chief executive officer, responsible for overall strategy and investment committee decisions across all of Pharos' funds. The firm focuses on value-based care companies, targeting businesses designed to cut the total cost of healthcare while improving patient access and outcomes. Pharos typically invests between $25 million and $50 million per deal, and has now completed investments in 58 companies since inception.
2. Youngblood Enterprises
Before Pharos existed, Youngblood set up Youngblood Enterprises, Inc., a Dallas-registered company that served as his initial commercial vehicle in the early 1990s. The firm gave him early exposure to the economics of healthcare consulting and business services, and let him convert his clinical background into market-facing strategy at a time when most physicians remained inside hospital systems. It served as the foundational block from which the larger Pharos platform was eventually built.
3. Pharos Financial Services
Sitting alongside the private equity operations, Pharos Financial Services is a separate entity in which Youngblood holds a majority ownership and managing director position. It handles broader investment management and strategic financial advisory work, giving him a more flexible vehicle to pursue market opportunities outside the direct equity and buyout framework his main fund operates within. The same analytical discipline that drives Pharos Capital runs through this entity.
4. Light & Wonder
Youngblood joined the board of what was then Scientific Games in 2018 and now serves as lead director of Light & Wonder, the company's rebranded successor. Listed on both the New York Stock Exchange and the Australian Securities Exchange, Light & Wonder operates in the global gaming and entertainment market, producing cross-platform games and systems. His governance role has been central to the company's shift away from its legacy lottery supply business toward a digital-first gaming strategy.
5. Core Scientific
Youngblood holds a board seat and investment interest in Core Scientific, one of North America's largest high-performance computing operators. The company runs data center infrastructure supporting bitcoin mining and other compute-intensive applications, and has positioned its operations around carbon-neutral energy sourcing. His involvement signals an investor comfortable navigating the regulatory and technical complexity of digital infrastructure, a sector far from his medical origins.
6. Energy Future Holdings
Formerly known as TXU, Energy Future Holdings was a Texas-based electricity producer at the center of a $45 billion leveraged buyout completed in 2007, one of the largest such transactions in American history. Youngblood served as a director and investor in the company. His broader energy credentials include a Senate-confirmed presidential appointment by Bill Clinton to the board of the United States Enrichment Corporation, where the task was to oversee the privatization of nuclear fuel production.
7. Mallinckrodt Pharmaceuticals
Youngblood has held a directorship and investment stake in Mallinckrodt plc, a specialty pharmaceutical company with operations across branded drugs, generic treatments and hospital imaging agents. His board tenure coincided with a significant period of restructuring and product pipeline shifts at the company. The role fits neatly inside his consistent investment thesis: healthcare businesses operating at the intersection of clinical need, cost reduction and underserved patient access.
